Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia.

Chen, Christine I; Paul, Harminder; Wang, Trina; Le, Lisa W; Dave, Nimisha; Kukreti, Vishal; Nong Wei, Ellen; Lau, Anthea; Bergsagel, Peter Leif; Trudel, Suzanne

Chen, Christine I; Paul, Harminder; Wang, Trina; Le, Lisa W; Dave, Nimisha; Kukreti, Vishal; Nong Wei, Ellen; Lau, Anthea; Bergsagel, Peter Leif; Trudel, Suzanne.

Affiliation

Chen CI; Princess Margaret Cancer Centre/Ontario Cancer Institute, Toronto, ON, Canada. christine.chen@uhn.ca.

Br J Haematol ; 165(5): 731-3, 2014 Jun.

Article in En | MEDLINE | ID: mdl-24611934

Subject(s)

Angiogenesis Inhibitors/therapeutic use; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy; Thalidomide/analogs & derivatives; Adult; Aged; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Thalidomide/therapeutic use; Treatment Outcome

Key words

IMiDs; chronic lymphocytic leukaemia; therapy

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Thalidomide / Leukemia, Lymphocytic, Chronic, B-Cell / Angiogenesis Inhibitors Type of study: Observational_studies / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2014 Type: Article

Fulltext

XML

PubMed Links

Search on Google